Fenofibric Acid Capsule, Delayed Release
NDC Package 69315-282-09
Package Information
Fenofibric Acid capsules is fenofibric acid delayed-release capsules areĀ indicated as adjunctive therapy to diet:to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (TG greater than or equal to 500 mg/dL).to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia when use of recommended LDL-C lowering therapy is not possible.Limitations of Use Markedly elevated levels of serum TG (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. This formulation utilizes a capsule, delayed release delivery system. Marketed by Leading Pharma, Llc, this product is identified by NDC 69315-282 and is authorized under FDA application ANDA211626.
Identification & Billing
- RxCUI: 828373 - fenofibric acid 135 MG Delayed Release Oral Capsule
- RxCUI: 828379 - fenofibric acid 45 MG Delayed Release Oral Capsule
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69315 - Leading Pharma, Llc
- 69315-282 - Fenofibric Acid
- 69315-282-09 - 90 CAPSULE, DELAYED RELEASE in 1 BOTTLE
- 69315-282 - Fenofibric Acid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69315-282-09 identifies a specific commercial package of 90 capsule, delayed release in 1 bottle of Fenofibric Acid, a human prescription drug labeled by Leading Pharma, Llc. This capsule, delayed release is formulated for oral use and contains fenofibric acid as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Leading Pharma, Llc on July 18, 2019. The current certification is valid through December 31, 2026.
How is this Leading Pharma, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69315028209. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 90 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.